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 Granuloma annulare (GA) is a granulomatous inflam-
matory skin disorder with localized or disseminated dis-
tribution of the papular lesions. The pathogenesis re-
mains enigmatic and effective treatment options are still 
missing  [1–3] . Various topical and systemic treatment ap-
proaches have been shown to be effective only in a minor-
ity of patients  [1, 2] , e.g. topical application of glucocor-
ticoids, ascomycin or vitamin E, PUVA (psoralen and 
UVA) therapy, systemic use of dapsone, ciclosporine, 
isotretinoin, fumaric acid esters, allopurinol, TNF-  an-
tagonists and others. As GA is a benign, often asymptom-
atic, skin disease, the risk-benefit ratio of systemic ther-
apy is poor, and therefore systemic therapy is generally 
not recommended. Interestingly, remissions may be in-
duced by a skin biopsy of the lesion or can occur sponta-
neously. 
 Inspired by a case report showing photodynamic ther-
apy (PDT) to be effective in a patient with GA  [4] , we 
sought to evaluate the therapeutic potential of PDT upon 
GA in a series of patients.
 Patients and Methods 
 Seven consecutive patients (3 women, 4 men; mean age, 55 
years) with histologically confirmed disseminated GA (3–12 le-
sions) from our outpatient clinic were included in this study. None 
of the patients had diabetes mellitus. The mean duration of GA 
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 Abstract 
 Background: Granuloma annulare (GA) is a benign granulo-
matous and inflammatory skin disorder. The pathogenesis 
remains enigmatic and convincingly effective treatment op-
tions are not available. Inspired by a report showing photo-
dynamic therapy (PDT) to be effective in a single patient with 
GA, we sought to evaluate this benefit in a series of patients 
with GA.  Observations: PDT was performed in 7 consecutive 
patients with histologically confirmed GA located at the ex-
tremities. First, 20% ALA gel was applied under an occlusive 
dressing for 5 h, followed by illumination with 100 J/cm 2 by 
a standard red-light source. In total, 2–3 PDT sessions were 
performed, with an interval of 2–4 weeks between each ses-
sion. Treatment was stopped when complete remission was 
achieved or when GA lesions remained unchanged after 2 
consecutive PDT sessions. The overall response rate was 
57%. In 2 patients (29%), GA cleared completely, in 2 patients 
(29%) the skin lesions improved markedly and in 3 patients 
(43%) no clinical response could be observed.  Conclusion: 
These promising results should be evaluated in larger con-
trolled studies. In selected patients, PDT might be a valuable 
recruit for the sparse armory available to treat GA. 
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was 4 years (4 months to 9 years). In each patient, at least 1 con-
servative treatment modality had been previously ineffective ( ta-
ble 1 ). The most cosmetically bothersome lesions were chosen, the 
worst lesion first, as targets for PDT. The GA lesions were located 
on the dorsum of the hands (4 patients), the lower limbs (1 pa-
tient), the lower arm (1 patient) or the elbow (1 patient;  table 1 ). 
 To begin, 20% 5-ALA gel (5-aminolevulinic acid HCl, 1.0 g; 
aqua ad injectabila, 1.9 g; dimethyl sulfoxide, 2.0 g; Tylose H 300 
ad, 5.0 g)  [5] was applied under an occlusive dressing for 5 h, fol-
lowed by illumination with 100 J/cm 2 by a commercial standard 
red-light source (Waldmann PDT 1200, 635 nm). To exclude an 
intrinsic therapeutic effect by the red-light irradiation itself, the 
contralateral hand in patients with both hands affected (n = 2) 
was illuminated with red light, i.e. without pretreatment 5-ALA. 
PDT was performed every 2–4 weeks, up to a total of 3 sessions 
depending on the lesions’ responses. PDT was stopped when the 
GA lesions cleared or if no clinical improvement could be seen 
after 2 consecutive PDT sessions.
 Results 
 The side effects during and after PDT were compara-
ble to the common side effects of PDT for other skin dis-
eases, and included mild to strong local pain and inflam-
matory reactions. The mean pain score, assessed by a vi-
sual analog scale (range 0 = no pain to 10 = unbearable 
pain) immediately after each illumination, was 5.2 (range 
0–8) for the first and 4.6 (range 0.5–7.5) for the second 
PDT treatment. Local cooling was provided during illu-
mination by a commercial cold air flow system (Cryo 5; 
Zimmer Electronics). Four of the 7 patients took 1 g 
paracetamol and 30 mg codeine orally 1 h before the PDT 
session. Local anasthesia with 1% mepivacaine subcuta-
neously was applied in 3 patients who noticed stronger 
pain during PDT. The mean pain score was higher in re-
sponders to PDT than in nonresponders (5.9 vs. 4.3 at the 
first PDT session). Shortly after treatment, all patients 
experienced a mild to severe local inflammation, edema, 
crust and scaling. Moderate exudation occurred in 1 pa-
tient. Within 2 days after PDT, the edema disappeared. 
Scales and crusts did not persist longer than 2 weeks. A 
complete clinical remission with a slight transitional hy-
perpigmentation of the target lesions was achieved in 2 
patients (29%;  fig. 1 ). The remission was stable over a 6-
month follow-up period. In 2 patients, the skin lesions 
improved markedly. Improvement was defined as a clin-
ically marked decrease in thickness or a reduction in size 
of the lesions. One of the patients with significant im-
provement decided to discontinue PDT because of side 
effects, i.e. mild local pain and inflammation. In this pa-
tient, the PDT-induced improvement was taken to a com-
plete remission by 18 sessions of bath PUVA therapy (cu-
mulative dose 25.5 J/cm 2 ). In 3 patients, no clinical re-
sponse could be observed. A histological follow-up was 
not performed. An average of 3 PDT cycles was required 
to achieve a complete remission. There was no significant 
correlation between the outcome of PDT treatment and 
the patients’ sex, skin type, previous treatment modali-
ties or the duration of the disease. The clinical side ef-
fects, apart from pain, were independent of the clinical 
response to PDT. Irradiation with red light alone had no 
effect on the GA lesions. In 2 patients with both hands 
affected, only the PDT-treated side healed, while the oth-
er hand exposed to only red light remained unchanged. 
The subsequent treatment of the control side with PDT 
eventually led to healing of the GA as well.
Table 1. Patient data regarding history, histological thickness of GA and PDT
Patient
No.
Age/sex Duration 
of disease 
years
Skin type
(I–VII)
Previous 
treatment
Target lesion Histological 
depth of lesion 
mm
PDT
sessions
Outcome
1 64/m 2 II TS, dorsum of hands 1.3 3 complete remission
2 59/m 5 II TS, UV dorsum of hands n.a. 3 no change
3 74/m 9 III TS, SS, UV elbow 1.7 2 improvement
4 50/m 3 III TS, SS, UV dorsum of hands 1.2 3 complete remission
5 25/f 4 months II TS lower limbs 1.4 2 no change
6 70/f 4 I–II TS, UV dorsum of hands n.a. 2 improvement 
7 56/f 5 II TS lower arm 1.0 2 no change
TS = Topical application of glucocorticoids; UV = ultraviolet treatment; SS = systemic glucocorticoids; n.a. = not available.
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 Discussion 
 PDT is a well-established treatment modality for der-
mato-oncologic disorders such as actinic keratoses, Bow-
en’s disease and superficial basal cell carcinoma. Further-
more, certain benefits of PDT have been reported anec-
dotally for inflammatory dermatoses, such as localized 
scleroderma or acne vulgaris  [5] , as well as for viral warts 
 [6] . A single case report on the efficacy of PDT in GA sug-
gested that PDT might also be a therapeutic option for 
this often incurable disease. Indeed, in 4 of 7 patients 
(57%) with therapy-resistant GA, complete healing (2/7) 
or profound improvement (2/7) could be achieved by 
PDT, while no effect was observed following illumination 
with red light alone. The mechanisms responsible for this 
effect are not yet understood. GA is a granulomatous skin 
disease characterized by necrobiotic granulomas. Granu-
loma formation most likely depends on type 1 T helper 
cells that activate macrophages to coexpress tumor ne-
crosis factor-  and metalloproteinases (MMP-2 and 
MMP-9) that finally promote matrix degradation  [7] . 
 The efficacy of PDT in GA might depend on its ability 
to induce T cell apoptosis. The penetration of PDT into 
the epidermis and superficial dermis of the human skin 
is generally limited to 3 mm. The histological depth of the 
GA lesions in our patients was 1.7 mm at maximum, mea-
sured from the stratum granulosum down to the bottom 
of the lesion. Thus, all lesions should have been within the 
scope of PDT. Since the paralesional inflammatory infil-
trate may extend from the corium to deeper skin layers, 
the sensitivity of GA to PDT may depend on the extent 
and level of granuloma formation throughout the skin. In 
particular, the deeper or subcutaneous forms of GA may 
not be sufficiently reached by PDT to achieve healing, 
which explains the lack of response in 3 of the 7 patients 
reported here. Hypothetically, solid strands of collagen 
within the GA may decrease the penetration of red light. 
However, no relevant differences in the presence and dis-
tribution of collagen strands could be noticed histopath-
ologically when comparing responsive and nonrespon-
sive GA lesions.
 The side effects during and after PDT were similar to 
the side effects observed in other indications. This sup-
ports the suggestion that cells in the GA lesions had ac-
tively metabolized 5-ALA into the photoactive protopor-
phyrin IX. The pain during PDT for actinic keratosis or 
basal cell carcinoma usually increases from the first to 
the second PDT session  [8] . However, in our patients, the 
pain assessed by a visual analog scale decreased from the 
first to the second PDT session. It is possible, but unlike-
ly, that there might be disease-specific differences re-
garding the PDT-induced pain course. More likely, this 
difference might be explained by the varying intervals 
between the sessions. The usual interval between two 
PDT sessions for actinic keratosis is between 7 and 15 
days. Hence, the second PDT is usually performed while 
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 Fig. 1.  a Granuloma annulare at the dorsum of both hands (ring-shaped and disseminated erythematous pap-
ules before PDT).  b Complete remission with hyperpigmentation after three PDT sessions. 
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the inflammation of the treated site – induced by the first 
session – is still ongoing. This could plausibly explain a 
certain aggravation in pain levels. If the second PDT is 
not performed until after 2 weeks have passed, the local 
inflammation of the first session will have already sub-
sided. In this study, PDT was only performed every 2–4 
weeks. 
 The promising results of the current study have to be 
evaluated in larger controlled studies. They hold promise 
that PDT might be a substantial addition to the sparse 
armory available to treat GA.
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